We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
EXDENSUR GlaxoSmithKline Australia Pty Ltd
Product name
EXDENSUR
Accepted date
Jun-2025
Active ingredients
depemokimab
Proposed indication
EXDENSUR (depemokimab) is used as an add-on treatment for:
-asthma in which eosinophils, a type of white blood cell, is present in the airways. It is for patients whose asthma is not controlled despite the use of both an inhaled corticosteroid and another asthma controller.
-inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a condition characterised by inflammation of the sinuses and nasal passages and the presence of soft tissue growths (nasal polyps).
-asthma in which eosinophils, a type of white blood cell, is present in the airways. It is for patients whose asthma is not controlled despite the use of both an inhaled corticosteroid and another asthma controller.
-inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a condition characterised by inflammation of the sinuses and nasal passages and the presence of soft tissue growths (nasal polyps).
Application type
A (new medicine)
Publication date
Jun-2025